Danaher Corporation (DHR)
Market Cap | 184.02B |
Revenue (ttm) | 23.89B |
Net Income (ttm) | 4.74B |
Shares Out | 739.70M |
EPS (ttm) | 6.38 |
PE Ratio | 39.13 |
Forward PE | 32.40 |
Dividend | $1.08 (0.43%) |
Ex-Dividend Date | Mar 27, 2024 |
Volume | 947,076 |
Open | 248.34 |
Previous Close | 248.77 |
Day's Range | 247.20 - 250.79 |
52-Week Range | 182.09 - 259.00 |
Beta | 0.86 |
Analysts | Buy |
Price Target | 269.93 (+7.85%) |
Earnings Date | Apr 23, 2024 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and service... [Read more]
Financial Performance
In 2023, Danaher's revenue was $23.89 billion, a decrease of -10.33% compared to the previous year's $26.64 billion. Earnings were $4.74 billion, a decrease of -33.23%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $269.93, which is an increase of 7.85% from the latest price.
News
Danaher Schedules First Quarter 2024 Earnings Conference Call
WASHINGTON , March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 ...
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON , Feb. 27, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conferen...
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
WASHINGTON , Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with ...
Danaher Announces Quarterly Dividend
WASHINGTON , Feb. 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common s...
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expa...
Danaher forecasts revenue decline in 2024, shares fall
Life sciences firm Danaher forecast a low single-digit percentage decline year-over-year in its 2024 adjusted core revenue on Tuesday, sending the shares down nearly 4% before the bell.
Danaher Reports Fourth Quarter and Full Year 2023 Results
WASHINGTON , Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only ...
Charts turn bullish on health-care stocks as sector takes early lead in 2024
Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h...
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devast...
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compan...
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 202...
Will Danaher Stock Rebound To Pre-Inflation Shock Highs Of $300?
Danaher stock (NYSE: DHR), a conglomerate with products in environmental, life sciences, and diagnostics fields, trades at $220 per share, about 2% below the level seen in March 2021. DHR stock was tr...
Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
Danaher Completes Acquisition of Abcam
WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for...
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a def...
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam today announced that all Identified Clearances required in connection with the acquisition of the company by Danaher have been obtained.
Abcam shareholders approve $5.7 billion Danaher deal
Abcam shareholders on Monday approved the proposal from Danaher Corp to acquire all outstanding shares of the company for $24 per share in cash.
Shareholders of Abcam Approve Proposed Acquisition by Danaher
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Shareholders of Abcam approve proposed acquisition by Danaher.
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc (“A...
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
WASHINGTON , Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Rile...
Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.
Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...